Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial
Related Posts
Matsumoto H, Higuchi S, Li D, Tanisawa H, Isodono K, Irie D, Ohya H, Kitamura R, Kaneko K, Nakazawa M, Suzuki K, Komori Y, Hondera[...]
Echegaray F, Hernandez CJ, Sundar KG, Yang LZ, Cambou MC, Segura ER, de Melo MG, Santos BR, Dos Santos Varella IR, Nielsen-Saines K. Repercussions of[...]
Fetters KB, Fernandez-Hazoury D, Grujic S, Lee P. Disseminated coccidioidomycosis presenting as eosinophilic ascites. BMJ Case Rep. 2025 Apr 15;18(4):e263734. doi: 10.1136/bcr-2024-263734. PMID: 40234081.